Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127305361 | 12730536 | 1 | I | 20160826 | 20160910 | 20160910 | EXP | JP-ALVOGEN-2016-ALVOGEN-028379 | ALVOGEN | FUNATSU Y, HIRAYAMA M, SHIRAISHI J, ASAKURA T, WAKAKI M, YAMADA E ET AL. INTIMAL SARCOMA OF THE PULMONARY ARTERY TREATED WITH PAZOPANIB. INTERNAL MEDICINE. 2016; 55:16: 2197-2202 | 71.00 | YR | M | Y | 0.00000 | 20160910 | MD | JP | JP |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127305361 | 12730536 | 1 | PS | DOXORUBICIN | DOXORUBICIN | 1 | MG/ML ON DAYS 1-3, EVERY 3 WEEKS | 65515 | 25 | MG | |||||||||
127305361 | 12730536 | 2 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | G/M2 ON DAYS 1-4, EVERY 3 WEEKS | 0 | 2.5 | MG | |||||||||
127305361 | 12730536 | 3 | SS | PAZOPANIB | PAZOPANIB | 1 | 0 | 800 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127305361 | 12730536 | 1 | Sarcoma |
127305361 | 12730536 | 2 | Sarcoma |
127305361 | 12730536 | 3 | Sarcoma |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127305361 | 12730536 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127305361 | 12730536 | Fatigue | |
127305361 | 12730536 | Neutropenia | |
127305361 | 12730536 | Pulmonary necrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |